Jean-Luc M. Lemercier - 08 Mar 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEACLA and JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Mar 2023
Net transactions value
-$277,290
Form type
4
Filing time
08 Mar 2023, 16:57:04 UTC
Previous filing
11 Jul 2022
Next filing
06 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $233,706 +6,640 +3.9% $35.20 175,515 08 Mar 2023 Direct F1
transaction EW Common Stock Sale $3,872 -50 -0.03% $77.43 175,465 08 Mar 2023 Direct F1
transaction EW Common Stock Sale $507,125 -6,590 -3.8% $76.95 168,875 08 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -6,640 -33% $0.000000 13,280 08 Mar 2023 Common Stock 6,640 $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $76.43 to $77.36 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.